Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes

Ophthalmology. 2009 Mar;116(3):544-551.e1. doi: 10.1016/j.ophtha.2008.10.014. Epub 2009 Jan 20.

Abstract

Purpose: To evaluate chemoreduction (CRD) for group E retinoblastoma.

Design: Retrospective, comparative case series.

Participants: Seventy-six eyes of 56 patients with group E retinoblastoma were treated with CRD alone or CRD plus low-dose prophylactic external beam radiotherapy (CRD+P-EBR). The CRD included vincristine, etoposide, and carboplatin (6 cycles). The P-EBR was given routinely 2 months after completion of CRD at a suggested dose of 2600 cGy. Therapeutic EBR (T-EBR) was only given at the time of extensive tumor recurrence at a suggested dose of 3800 cGy.

Methods: Retrospective chart review.

Main outcome measures: Globe salvage.

Results: Of the 76 eyes, 64 received CRD alone and 12 received CRD+P-EBR. At the 2-year follow-up, globe salvage was achieved in 29 (53%) of 55 eyes in the CRD group and in 10 (91%) of 11 eyes in the CRD+P-EBR group. At 5 years, globe salvage was achieved in 20 (48%) of 42 eyes in the CRD group and in 4 (80%) of 5 eyes in the CRD+P-EBR group (P=0.347). Of the 64 eyes in the CRD group, 16 (25%) were salvaged with CRD alone and 13 (20%) with CRD+T-EBR, whereas 22 (34%) were enucleated after CRD alone and 13 (20%) were enucleated after CRD+T-EBR. Of the 12 eyes in the CRD+P-EBR group, 10 (83%) were salvaged with CRD+P-EBR, whereas 2 (17%) were enucleated and none required T-EBR. The median dose for T-EBR was 3800 cGy, and that for P-EBR was 2600 cGy. Eyes treated with CRD+P-EBR showed significantly less recurrence, leading to less chance of enucleation or therapeutic radiotherapy than that for CRD alone (P<0.001). Visual acuity was 20/100 or better or fix and follow in 9 (32%) of 28 salvaged eyes in the CRD group and in 4 (40%) of 10 in the CRD+P-EBR group. At 5 years, there were no patients in either group with metastasis of pinealoblastoma or who had died. In one patient in the CRD group, a second cancer developed.

Conclusions: Group E retinoblastoma managed with CRD+P-EBR showed significantly less need for enucleation or therapeutic radiotherapy than eyes treated with CRD alone. These findings merit further study and consideration.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / therapeutic use
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Etoposide / therapeutic use
  • Eye Enucleation
  • Female
  • Humans
  • Infant
  • Male
  • Neoplasm Recurrence, Local
  • Radiotherapy, High-Energy*
  • Retinal Neoplasms / classification
  • Retinal Neoplasms / drug therapy
  • Retinal Neoplasms / radiotherapy
  • Retinal Neoplasms / therapy*
  • Retinoblastoma / classification
  • Retinoblastoma / drug therapy
  • Retinoblastoma / radiotherapy
  • Retinoblastoma / therapy*
  • Retrospective Studies
  • Treatment Outcome
  • Vincristine / therapeutic use
  • Visual Acuity

Substances

  • Vincristine
  • Etoposide
  • Carboplatin

Supplementary concepts

  • CEV regimen